Societe Internationale d'Oncologie Pediatrique – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 45
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S1B8FDB4A41EN
Leaflet:

Download PDF Leaflet

Societe Internationale d'Oncologie Pediatrique – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Societe Internationale d'Oncologie Pediatrique – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Societe Internationale d'Oncologie Pediatrique – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Societe Internationale d'Oncologie Pediatrique human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Societe Internationale d'Oncologie Pediatrique with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Societe Internationale d'Oncologie Pediatrique’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Societe Internationale d'Oncologie Pediatrique’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Societe Internationale d'Oncologie Pediatrique in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Societe Internationale d'Oncologie Pediatrique’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Societe Internationale d'Oncologie Pediatrique.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Societe Internationale d'Oncologie Pediatrique and identify potential opportunities in those areas.
Societe Internationale d'Oncologie Pediatrique Snapshot
Societe Internationale d'Oncologie Pediatrique Overview
Key Information
Key Facts
Societe Internationale d'Oncologie Pediatrique – Research and Development Overview
Key Therapeutic Areas
Societe Internationale d'Oncologie Pediatrique – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Combination Treatment Modalities
Societe Internationale d'Oncologie Pediatrique – Pipeline Products Glance
Societe Internationale d'Oncologie Pediatrique – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Societe Internationale d'Oncologie Pediatrique Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Societe Internationale d'Oncologie Pediatrique – Drug Profiles
Carboplatin + Cisplatin + Doxorubicin hydrochloride
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Vincristine + Cyclophosphamide + Etoposide + radiation theraphy
  Product Description
  Mechanism of Action
  R&D Progress
Carboplatin + Vincristine Sulfate
  Product Description
  Mechanism of Action
  R&D Progress
Cisplatin + Carboplatin + Doxorubicin
  Product Description
  Mechanism of Action
  R&D Progress
Cisplatin + Doxorubicin Hydrochloride
  Product Description
  Mechanism of Action
  R&D Progress
dactinomycin + carboplatin + cyclophosphamide + epirubicin hydrochloride + etoposide + ifosfamide + vincristine sulfate
  Product Description
  Mechanism of Action
  R&D Progress
cyclophosphamide + etoposide + vincristine sulfate + radiation therapy
  Product Description
  Mechanism of Action
  R&D Progress
Cyclophosphamide + Etoposide + Vincristine sulfate + Radiation therapy
  Product Description
  Mechanism of Action
  R&D Progress
dactinomycin + filgrastim + carboplatin + cyclophosphamide + doxorubicin hydrochloride + epirubicin hydrochloride + etoposide + ifosfamide + vincristine sulfate
  Product Description
  Mechanism of Action
  R&D Progress
Dactinomycin + Filgrastim + Carboplatin + Cylophosphamide + Doxorubicin + Epirubicin + Etoposide + Ifosfamide + Vincristine
  Product Description
  Mechanism of Action
  R&D Progress
Societe Internationale d'Oncologie Pediatrique – Pipeline Analysis
Societe Internationale d'Oncologie Pediatrique – Pipeline Products by Therapeutic Class
Societe Internationale d'Oncologie Pediatrique Pipeline Products By Target
Societe Internationale d'Oncologie Pediatrique – Pipeline Products by Route of Administration
Societe Internationale d'Oncologie Pediatrique – Pipeline Products by Molecule Type
Societe Internationale d'Oncologie Pediatrique – Locations And Subsidiaries
Head Office
Recent Developments
May 07, 2010: Eisai To Initiate Japan Clinical Trial Of Rufinamide In Lennox-Gastaut Syndrome Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 45

LIST OF TABLES

Societe Internationale d'Oncologie Pediatrique – Pipeline by Therapy Area and Indication, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline by Stage of Development, 2010
Societe Internationale d'Oncologie Pediatrique – Combination Treatment Modalities in Pipeline, 2010
Societe Internationale d'Oncologie Pediatrique – Phase III, 2010
Societe Internationale d'Oncologie Pediatrique - Phase II, 2010
Societe Internationale d'Oncologie Pediatrique - Pipeline By Therapeutic Class, 2010
Societe Internationale d'Oncologie Pediatrique - Pipeline By Target, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline By Route of Administration, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline By Molecule Type, 2010 41

LIST OF FIGURES

Societe Internationale d'Oncologie Pediatrique – Pipeline by Therapy Area and Indication, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline by Stage of Development, 2010
Societe Internationale d'Oncologie Pediatrique – Combination Treatment Modalities in Pipeline, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline By Therapeutic Class, 2010
Societe Internationale d'Oncologie Pediatrique - Pipeline By Target, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline By Route of Administration, 2010
Societe Internationale d'Oncologie Pediatrique – Pipeline By Molecule Type, 2010 41

Ask Your Question

Societe Internationale d'Oncologie Pediatrique – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: